 InPharm | Bayer drug enters phase III for diabetic macular oedema InPharm DME is a common complication of diabetic retinopathy and involves fluid collection in the macula. It is the most prevalent cause of moderate vision loss in patients with diabetes and the number of patients are growing as diabetes becomes more ... Regeneron And Bayer Announce Start Of Phase 3 Clinical ProgramPharmaceutical Online (press release) Bayer/Regeneron's VEGF Trap-Eye into Phase III for DMEPharma Times all 6 news articles » |
April 12, 2011
Bayer drug enters phase III for diabetic macular oedema - InPharm
Bayer drug enters phase III for diabetic macular oedema - InPharm: "
"
